A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer n. MK6070-003
Phase: Phase I-II clinical trials
Principal Investigator: Dott. Occhipinti Mario
Main Facility: Oncologia Medica 1
Drug: MK-6070 e Ifinatamab Derux-tecan (MK-2400)
Pathologies: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
Phase 1b/2, open-label clinical trial for patients with extensive-stage small cell lung cancer who have not yet received treatment for this stage of disease (first-line). The objective is to evaluate the effectiveness and safety of different investigational drug combinations compared to the standard of care. Participants are assigned to one of four treatment groups (parallel arms). The first three groups (Arms 1, 2, and 3) receive the investigational drugs MK-6070 and Ifinatamab Deruxtecan (I-DXd / MK-2400) via intravenous infusion every 3 weeks; the third group (Arm 3) also adds a third drug, Atezolizumab. The fourth group (Arm 4) receives the standard comparator therapy, consisting of a combination of three drugs (Atezolizumab, Carboplatin, and Etoposide) administered via intravenous infusion every 3 weeks.
Last update: 06/10/2026